<DOC>
	<DOCNO>NCT01238562</DOCNO>
	<brief_summary>This study ass safety , tolerability , pharmacokinetics , pharmacodynamics single-dose YPEG-Filgrastim cancer patient receive chemotherapy , establish dose-response relationship YPEG-Filgrastim Filgrastim ( rhG-CSF , TOPNEUTER ) .</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacokinetics Pharmacodynamics Study YPEG-Filgrastim Chemotherapy Patients</brief_title>
	<detailed_description />
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Age : 18～70yrs Signed inform consent Confirmed malignant tumor patient histopathological cytological diagnosis , suitable chemotherapy carboplatin combine taxol cyclophosphamide combine pharmorubicin Karnofsky score ≥70 Life expectancy &gt; 3 month WBC≥3,500 per cubic milliliter , ANC≥1,500 per cubic milliliter , PLT≥100,000 per cubic milliliter Normal coagulation function , evidence hemorrhage Normal liver , heart , kidney function Pregnant lactating female Proven active infectious disease ( e.g . viral hepatitis , TB ) Not adequately controlled infection Known hypersensitivity filgrastim component study drug Unstable uncontrolled cardiac disease hypertension Currently participate clinical trial Patients previous expect receive systemic radiotherapy Evidence metastatic disease bone marrow , brain , et al Alcoholic drug abuser Other condition opinion investigator preclude enrollment study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>cancer patient</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>carboplatin</keyword>
	<keyword>taxol</keyword>
	<keyword>cyclophosphamide</keyword>
	<keyword>pharmorubicin</keyword>
</DOC>